



## **Ikena Oncology to Participate in November 2021 Virtual Investor Conferences**

November 4, 2021

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena"), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that management will participate in several virtual investor conferences in November 2021.

Details are as follows:

**Conference: BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology**

Panel; Emerging Trends in Oncology: Targeted Therapies and Other Novel Treatment Modalities

Date: Monday, November 8, 2021, 3:25pm EST; available for replay following the event

**Conference: Credit Suisse 30<sup>th</sup> Annual Healthcare Conference**

Fireside Chat; Investor Meetings

Date: Thursday, November 11, 2021, 3:30pm EST; live and available for replay

[Webcast Link](#)

**Conference: Stifel 2021 Virtual Healthcare Conference**

Corporate Presentation; Investor Meetings

Date: Monday, November 15, 2021, 11:20am EST; live and available for replay

[Webcast Link](#)

**Conference: Jefferies London Healthcare Conference**

Corporate Presentation; Investor Meetings

Date: Thursday, November 18, 2021, 8:00am GMT; pre-recorded and available for replay

[Webcast Link](#)

The presentation webcasts can be accessed by visiting the Investors & Media section of the company's website at [www.ikenaoncology.com](http://www.ikenaoncology.com). The webcast will be archived for a period of 90 days following the conclusion of the live event.

### **About Ikena Oncology**

Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. The Company's lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. Additional programs include an ERK5 inhibitor program targeting the KRAS signaling pathway and programs targeting the tumor microenvironment and immune signals, two of which are being developed in collaboration with Bristol Myers Squibb, including IK-175, an aryl hydrocarbon receptor antagonist designed to modulate the tumor microenvironment. Ikena's pipeline is built on addressing genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit [www.ikenaoncology.com](http://www.ikenaoncology.com) or follow us on [Twitter](#) and [LinkedIn](#).

### **Media Contact:**

Gwen Schanker

LifeSci Communications

[gschanker@lifescicomms.com](mailto:gschanker@lifescicomms.com)

### **Investor Contact:**

Rebecca Cohen

Ikena Oncology

[rcohen@ikenaoncology.com](mailto:rcohen@ikenaoncology.com)